Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Neurogenic Orthostatic Hypotension
MSA - Multiple System Atrophy

Interventions

DRUG: Ampreloxetine
DRUG: Placebo

Sponsor

Theravance Biopharma